Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models

Overview of attention for article published in Frontiers in oncology, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 12 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 47,882 followers.

RT @Blagosklonny: "And dual inhibition of MET and EGFR might be a therapeutic strategy for EGFR-driven drug resistance METex14 lung cancer.…

28 Mar 2024

Reply Repost Favourite

"And dual inhibition of MET and EGFR might be a therapeutic strategy for EGFR-driven drug resistance METex14 lung cancer." https://t.co/XmezIo7pak

28 Mar 2024

Reply Repost Favourite

Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models: Background Non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14) occurs in 3-4% of… #oncology https://t.co/gN

24 Oct 2022

Reply Repost Favourite

New research: Integrative genomic analysis of drug resistance in MET exon 14 skipping lung cancer using patient-derived xenograft models: Background Non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14) occurs in 3-4% of… https://t.c

22 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.